Skip to main content

Advertisement

Table 2 Comparison of the different variables on CIS patients with or without conversion to clinically definite MS at the end of follow-up period

From: Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis

  CIS patients with conversion to clinically definite MS (n = 23) CIS patients without conversion to clinically definite MS (n = 28) p
Female sex 17 (73.9%) 21 (75%) 0.93
Mean age at MS diagnosis (years +/- SEM) 31.8 +/- 2.2 31.0 +/- 2.0 0.79
Mean age at treatment initiation (years +/- SEM) 33.4 +/- 2.5 32.1 +/- 2.0 0.69
Mean EDSS at inclusion consultation (+/- SEM) 1.2 +/- 0.2 1.3 +/- 0.2 0.77
Mean ΔEDSS* (+/- SEM) +0.2 +/- 0.04 0 +/- 0.02 0.70
Mean MFIS score (+/- SEM) 36.0 +/- 4.5 35.8 +/- 3.3 0.98
Number of fatigue patients 13 (56.5%) 16 (57.1%) 0.96
Mean MADRS score (+/- SEM) 3.7 +/- 0.8 3.2 +/- 0.5 0.63
Mean MSTCQ score (+/- SEM) 6.3 +/- 0.8 6.3 +/- 0.9 0.99
Number of NAb + patients 5 (21.7%) 7 (25.0%) 0.78
IFNβ type:    
- Intramuscular IFNβ-1a 2 (8.7%) 3 (10.7%) 0.43
- Subcutaneous IFNβ-1a 16 (69.6%) 15 (53.6%)  
- Subcutaneous IFNβ-1b 5 (21.7%) 10 (35.7%)  
  1. *ΔEDSS = EDSS at the follow-up consultation – EDSS at the inclusion consultation.